AI English summary of an SEC filing — figures as filed
Moderna MRNAModerna said that for the year ended December 31, 2024, it recognized net product sales of $3.1 billion from sales of its COVID and RSV vaccines, compared to $6.7 billion for 2023 and $18.4 billion for 2022. Loss per share was $(9.28) for 2024.
Key points
AI summaryModerna said that for the year ended December 31, 2024, it recognized net product sales of $3.1 billion from sales of its COVID and RSV vaccines, compared to $6.7 billion for 2023 and $18.4 billion for 2022. Loss per share was $(9.28) for 2024.
The company said total revenue in 2024 decreased by $3.6 billion (53%), primarily attributable to a significant reduction in net product sales. It cited lower sales volumes in Europe and the rest of the world as factors in the net product sales decline. U.S. sales included an approximately $216 million benefit related to a reversal of prior-year sales provisions, the company added.
Moderna said cost of sales in 2024 was $1.5 billion (47% of net product sales), including inventory write-downs of $495 million and wind-down costs of $263 million. Cost of sales in 2023 was $4.7 billion (70% of net product sales), the company said.
The company said it had a net cash outflow from operations of $3.0 billion for the year ended 2024 and net loss of $3.6 billion. Cash, cash equivalents and investments as of December 31, 2024 decreased by $3.8 billion (28%) compared to December 31, 2023.
Key figures
Fiscal year ended December 31, 2024
- Revenue
- $3.2B
- Operating income
- −$3.9B
- Net income
- −$3.6B
- EPS
- −$9.28
- Operating cash flow
- −$3.0B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
2024 Net Product Sales $3.1 billion, Loss Per Share $(9.28)
Moderna said that for the year ended December 31, 2024, it recognized net product sales of $3.1 billion from sales of its COVID and RSV vaccines, compared to $6.7 billion for 2023 and $18.4 billion for 2022. Loss per share was $(9.28) for 2024.
Source · Based on the MD&A text of the filing
Total Revenue Decreased $3.6 billion (53%)
The company said total revenue in 2024 decreased by $3.6 billion (53%), primarily attributable to a significant reduction in net product sales. It cited lower sales volumes in Europe and the rest of the world as factors in the net product sales decline. U.S. sales included an approximately $216 million benefit related to a reversal of prior-year sales provisions, the company added.
Source · Based on the MD&A text of the filing
Cost of Sales $1.5 billion, 47% of Net Product Sales
Moderna said cost of sales in 2024 was $1.5 billion (47% of net product sales), including inventory write-downs of $495 million and wind-down costs of $263 million. Cost of sales in 2023 was $4.7 billion (70% of net product sales), the company said.
Source · Based on the MD&A text of the filing
Net Cash Outflow From Operations $3.0 billion
The company said it had a net cash outflow from operations of $3.0 billion for the year ended 2024 and net loss of $3.6 billion. Cash, cash equivalents and investments as of December 31, 2024 decreased by $3.8 billion (28%) compared to December 31, 2023.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…